{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:15:42Z","timestamp":1778649342022,"version":"3.51.4"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the reporting characteristics and quality of patient-reported outcomes (PROs) in randomized controlled trials (RCTs) of targeted therapy and\/or immunotherapy for liver cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched six electronic databases for relevant RCTs published in English or Chinese from inception to April 17, 2025. The reporting quality of PROs was assessed using the CONSORT-PRO extension and the CONSORT 2010 guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 64 RCTs with 8,494 participants. Of these, 14 studies were confirmatory studies, 31 studies were exploratory studies and 19 studies were categorized as \u201cOther\u201d studies. 23.4% (15\/64) of these RCTs reported PROs as the primary outcome. Twenty-seven patient-reported outcome measures (PROMs) about 17 relevant domains were observed in these studies. The domain with the highest reporting frequency was quality of life (53\/64). Forty trials utilized a single PROM, while 24 trials employed multiple PROMs. The EORTC QLQ-C30 was the most often used PROM (25\/53). Nineteen trials employed single-domain symptoms or specific functioning PROMs. Eight symptomatic adverse events were reported in less than 30% of studies. The mean score of the CONSORT-PRO adherence was 7.5 (3-14) for confirmatory studies, 5.8 (4-9) for exploratory studies and 6.0 (3-9) for other studies. The adherence to CONSORT 2010 was poor among the included trials. Only 3 trials achieved good reporting quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among the 64 included RCTs, the reporting of specific symptoms and the application of specific PROMs related to targeted and\/or immunotherapy were poor. Meanwhile, the integration of PROs with clinical endpoints was suboptimal, and PRO data were seldom used to guide nursing practice. More importantly, the overall adherence to CONSORT-PRO among the included studies was low. Although confirmatory studies demonstrated higher scores than exploratory studies and other types of studies, there was considerable variation within this category. Future studies should prioritize the use of validated, standard disease-specific tools and strengthen the evaluation of treatment-related adverse events. Furthermore, we advocate establishing a collaborative framework that integrates medical, nursing, and patient perspectives. Future studies, particularly confirmatory studies and nursing intervention or supportive care studies, strictly adhere to the CONSORT-PRO guideline.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1770579","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:49:34Z","timestamp":1778647774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating patient-reported outcomes in randomized controlled trials of targeted therapy and\/or immunotherapy for liver cancer: a scoping review"],"prefix":"10.3389","volume":"16","author":[{"given":"Lu","family":"Ren","sequence":"first","affiliation":[{"name":"School of Nursing, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuntong","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Nursing, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangjin","family":"Li","sequence":"additional","affiliation":[{"name":"School of Nursing, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujin","family":"Yue","sequence":"additional","affiliation":[{"name":"School of Nursing, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Beijing University of Chinese Medicine Collaboration Center of Joanna Briggs Institute","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiang","family":"Su","sequence":"additional","affiliation":[{"name":"School of Nursing, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Beijing University of Chinese Medicine Collaboration Center of Joanna Briggs Institute","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Nursing, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Nursing, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: Esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-2021-7","article-title":"Combination therapy for advanced hepatocellular carcinoma: Do we see the light at the end of the tunnel","volume":"10","author":"Zhang","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/s0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (Resorce): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (Reach-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05695-4","article-title":"Patient outcomes, patient experiences and process indicators associated with the routine use of patient-reported outcome measures (Proms) in cancer care: A systematic review","volume":"29","author":"Graupner","year":"2021","journal-title":"Support Care Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"Jama"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance","volume":"4","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.08.072","article-title":"End points and United States Food and Drug Administration approval of oncology drugs","volume":"21","author":"Johnson","year":"2003","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-1099-z","article-title":"International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (Pro) measures in oncology studies","volume":"25","author":"Kyte","year":"2016","journal-title":"Qual Life Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/prom.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.11.071","article-title":"Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic","volume":"136","author":"Gilbert","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.53.5948","article-title":"What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials","volume":"32","author":"Kotronoulas","year":"2014","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2016.1164595","article-title":"Patient reported outcomes in randomized controlled cancer trials in advanced disease: A structured literature review","volume":"9","author":"Weing\u00e4rtner","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-010-9793-3","article-title":"Patterns of reporting health-related quality of life outcomes in randomized clinical trials: Implications for clinicians and quality of life researchers","volume":"20","author":"Brundage","year":"2011","journal-title":"Qual Life Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: The Consort Pro extension","volume":"309","author":"Calvert","year":"2013","journal-title":"Jama"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104345","article-title":"Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review","volume":"197","author":"Roets","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3390\/cancers15041135","article-title":"Role of patient-reported outcomes in clinical trials in metastatic colorectal cancer: A scoping review","volume":"15","author":"Maring","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(20)30292-1","article-title":"Quality of patient-reported outcome reporting in randomised controlled trials of haematological Malignancies according to international quality standards: A systematic review","volume":"7","author":"Chakraborty","year":"2020","journal-title":"Lancet Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7326\/m18-0850","article-title":"Prisma extension for scoping reviews (Prisma-Scr): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1508-6","article-title":"Preliminary evidence on the uptake, use and benefits of the Consort-Pro extension","volume":"26","author":"Mercieca-Bebber","year":"2017","journal-title":"Qual Life Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31930","article-title":"Use and reporting of patient-reported outcomes in trials of palliative radiotherapy: A systematic review","volume":"5","author":"Fabian","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B26","article-title":"E8(R1) General considerations for clinical studies","volume-title":"ICH Harmonised Guideline E8(R1)","year":"2022"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer Qlq-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the Sf-36 health survey questionnaire: New outcome measure for primary care","volume":"305","author":"Brazier","year":"1992","journal-title":"Bmj"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2012.121","article-title":"Euroqol-5d (Eq-5d): An instrument for measuring quality of life","volume":"78","author":"Balestroni","year":"2012","journal-title":"Monaldi Arch Chest Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3181b4b04f","article-title":"Development and validation of a quality of life instrument for patients with liver cancer Qol-Lc","volume":"33","author":"Wan","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20321","article-title":"The Dermatology Life Quality Index (Dlqi) used as the benchmark in validation of 101 quality-of-life instruments: A systematic review","volume":"39","author":"Vyas","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0219","article-title":"The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An assessment tool for oncology","volume":"20","author":"Anderson","year":"2015","journal-title":"Oncologist"},{"key":"B33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/nur.4770020105","article-title":"Development of an instrument to measure exercise of self-care agency","volume":"2","author":"Kearney","year":"1979","journal-title":"Res Nurs Health"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-022-03119-w","article-title":"Knowledge translation concerns for the Consort-Pro extension reporting guidance: A review of reviews","volume":"31","author":"Mercieca-Bebber","year":"2022","journal-title":"Qual Life Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (Ibi305) versus sorafenib in unresectable hepatocellular carcinoma (Orient-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Easl clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.017","article-title":"Patient-reported outcomes as independent prognostic factors for survival in oncology: Systematic review and meta-analysis","volume":"24","author":"Efficace","year":"2021","journal-title":"Value Health"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.13.3439","article-title":"The prognostic significance of patient-reported outcomes in cancer clinical trials","volume":"26","author":"Gotay","year":"2008","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3153","article-title":"Patient-reported outcomes as prognostic indicators for overall survival in cancer: A systematic review and meta-analysis","volume":"11","author":"Huang","year":"2025","journal-title":"JAMA Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.06.033","article-title":"Development of a questionnaire module to supplement the Eortc Qlq-C30 to assess quality of life in patients with hepatocellular carcinoma, the Eortc Qlq-Hcc18","volume":"40","author":"Blazeby","year":"2004","journal-title":"Eur J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (Rescue): A nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02827-9","article-title":"Recommendations to address respondent burden associated with patient-reported outcome assessment","volume":"30","author":"Aiyegbusi","year":"2024","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-025-04079-7","article-title":"Reducing patient burden of Proms in healthcare through advanced computerized adaptive testing stopping rules","volume":"34","author":"Luijten","year":"2025","journal-title":"Qual Life Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00847-2","article-title":"The impact of dermatologic adverse events on the quality of life of oncology patients: A review of the literature","volume":"25","author":"Belzer","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: Esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: A randomized clinical trial","volume":"327","author":"Basch","year":"2022","journal-title":"Jama"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e007555","DOI":"10.1136\/jitc-2023-007555","article-title":"Experience of patients considering or using checkpoint inhibitors in cancer treatment: A systematic review of qualitative research","volume":"12","author":"Yip","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/cmr.0000000000001014","article-title":"Patient-reported outcomes in randomized controlled trials evaluating Braf inhibitors in patients with cutaneous melanoma: A systematic scoping review of quality of reporting and trial results","volume":"35","author":"Al-Naesan","year":"2025","journal-title":"Melanoma Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-022-00538-8","article-title":"You need a team\": Perspectives on interdisciplinary symptom management using patient-reported outcome measures in hemodialysis care-a qualitative study","volume":"7","author":"Baragar","year":"2023","journal-title":"J Patient Rep Outcomes"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13388-5","article-title":"Systematic review of patient-reported outcome measures in locally recurrent rectal cancer","volume":"30","author":"McKigney","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-023-01332-1","article-title":"The impact of current therapeutic options on the health-related quality of life of patients with relapse\/refractory multiple myeloma: A systematic review of clinical studies","volume":"18","author":"Ojo","year":"2024","journal-title":"J Cancer Surviv"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz038","article-title":"Systematic evaluation of patient-reported outcome protocol content and reporting in cancer trials","volume":"111","author":"Kyte","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: Recommendations of the Sisaqol Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"B58","volume-title":"Fda patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making","year":"2025"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu489","article-title":"Poor patient-reported outcomes reporting according to Consort guidelines in randomized clinical trials evaluating systemic cancer therapy","volume":"26","author":"Bylicki","year":"2015","journal-title":"Ann Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-025-00766-y","article-title":"Adherence to Consort-Pro extension guidelines for patient-reported outcomes in randomized controlled trials focused on peripheral nerve blocks: A meta-epidemiological study","volume":"14","author":"Khan","year":"2025","journal-title":"Pain Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase iii randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (Tace 2): A randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (Sarah): An open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30146-3","article-title":"Tivantinib for second-line treatment of Met-High, advanced hepatocellular carcinoma (Metiv-Hcc): A final analysis of a phase 3, randomised, placebo-controlled study","volume":"19","author":"Rimassa","year":"2018","journal-title":"Lancet Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0892","article-title":"Sirvenib: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.04.021","article-title":"Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma","volume":"71","author":"Jouve","year":"2019","journal-title":"J Hepatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00110-2","article-title":"Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: Patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial","volume":"6","author":"Vogel","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33317","article-title":"Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: Keynote-240","volume":"127","author":"Ryoo","year":"2021","journal-title":"Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (Imbrave150): An open-label, randomised, phase 3 trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01462","article-title":"Patient-reported outcomes from the phase iii Himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"42","author":"Sangro","year":"2024","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (Emerald-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.4099","article-title":"Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (Hcc): A randomized multicenter phase ii trial (Sakk 77\/08 and Sasl 29)","volume":"32","author":"Koeberle","year":"2014","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.11569\/wcjd.v23.i33.5383","article-title":"Fuzheng Guben therapy improves quality of life in patients with hepatocellular carcinoma on targeted therapy","volume":"33","author":"Qiao","year":"2015","journal-title":"World Chin J Digestology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1002-3429.2015.06.032","article-title":"The effect of radiofrequency ablation combined with targeted therapy guided by ultrasound on quality of life of patients with advanced hepatocellular carcinoma","volume":"6","author":"Xulan","year":"2015","journal-title":"Clin Misdiagnosis Mistherapy"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1003-6350.2015.21.1141","article-title":"Clinical efficacy of radiofrequency ablation combined with Dc-Cik and its effect on quality of life in patients with advanced hepatocellular carcinoma","volume":"26","author":"Hongmei","year":"2015","journal-title":"Hainan Med J"},{"key":"B77","article-title":"Effects of gefitinib on pain degree and life quality in patients with middle and advanced liver cancer","volume":"24","author":"Hongxia","year":"2015","journal-title":"J Logistics Univ PAPF (Medical Scienees)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1005-9202.2017.01.048","article-title":"The influence of autologous cytokine-induced killer cells combined with targeted therapy for liver cancer on the quality of life of elderly patients with liver cancer","volume":"37","author":"Cuixia","year":"2017","journal-title":"Chin J Gerontology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.15887\/j.cnki.13-1389\/r.2018.02.074","article-title":"The influence of autologous cytokine-induced killer cells combined with targeted therapy for liver cancer on the quality of life of elderly patients with advanced liver cancer","volume":"11","author":"Shuiping","year":"2018","journal-title":"Chin J Clin Rational Drug Use"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.11569\/wcjd.v29.i4.182","article-title":"Effects of camrelizumab combined with transcatheter arterial chemoembolization arterial chemoembolization on serum Egfl7, Vegf, and Opn levels and recurrence rate in patients with hepatocellular carcinoma with microvascular invasion after radical operation: A prospective study","volume":"29","author":"Huang","year":"2021","journal-title":"World Chin J Digestology"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-744X.2021.06.019","article-title":"Analysis of the application value of interventional therapy combined with targeted drug apatinib in the treatment of primary liver cancer","volume":"45","author":"Pengtao","year":"2021","journal-title":"Guizhou Med J"},{"key":"B82","article-title":"The influence of transcatheter arterial chemoembolization combined with sorafenib and targeted intervention on the liver function levels of tumor markers in patients with liver cancer","volume":"42","author":"Wang","year":"2021","journal-title":"J Med Forum"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-4985.2022.09.038","article-title":"Clinical study of camrelizumab combined with lenvatinib in the treatment of advanced hepatocarcinoma","volume":"19","author":"Zefeng","year":"2022","journal-title":"Med Innovation China"},{"key":"B84","article-title":"The clinical efficacy and safety of sintilimab combined with lenvatinib as second-line treatment for unresectable hepatocellular carcinoma","volume":"9","author":"Wenqian","year":"2022","journal-title":"Chin Sci Technol J Database (Citation Edition): Med Health"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.19368\/j.cnki.2096-1782.2022.24.173","article-title":"Clinical efficacy of Tace combined with lenvatinib in the treatment of intermediate to advanced hepatocellular carcinoma","volume":"7","author":"Ping","year":"2022","journal-title":"Syst Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.14033\/j.cnki.cfmr.2022.31.009","article-title":"Effect of lenvatinib combined with transcatheter arterial chemoembolization on patients with advanced liver cancer","volume":"20","author":"Fengqi","year":"2022","journal-title":"Chin Foreign Med Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"9","DOI":"10.19335\/j.cnki.2096-1219.2023.31.003","article-title":"Targeted drugs combined with immunotherapy in patients with primary liver cancer complicated with microvascular invasion discussion on the value of development","volume":"9","author":"Feng","year":"2023","journal-title":"Smart Healthcare"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-6450.2023.01.010","article-title":"Effect of immunocheckpoint inhibitor combined with ranvartinib on Tace resistance to advanced primary liver cancer and its influence on serum Pdgf and Vegf","volume":"22","author":"Liang","year":"2023","journal-title":"Chin J Difficult Complicated cases"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-4931.2023.06.027","article-title":"Clinical study of sintilimab combined with radiofrequency ablation in the treatment of stage IIa liver cancer","volume":"32","author":"Fu","year":"2023","journal-title":"China Pharm"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.16190\/j.cnki.45-1211\/r.2023.11.015","article-title":"Efficacy of natural killer cell assisted radio frequency ablation on patients with liver cancer and its influence on T cell subsets and survival rate","volume":"40","author":"Zhichao","year":"2023","journal-title":"J Guangxi Med Univ"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.16458\/j.cnki.1007-0893.2023.23.035","article-title":"Observation on the therapeutic effect of transcatheter arterial chemoembolization combined with transcatheter arterial infusion chemotherapy on advanced liver cancer","volume":"33","author":"Quanhui","year":"2023","journal-title":"Shenzhen J Integrated Traditional Chin Western Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1008-1704.2023.12.012","article-title":"The clinical efficacy of tirelizol on the treatment of advanced liver cancer and its influence on peripheral Prmt5 and Pivka-II levels","volume":"28","author":"Haihui","year":"2023","journal-title":"Chin Hepatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-9455.2024.07.024","article-title":"Effect of sorafenib tosylate tablets combined with oxaliplatin in treatment of chemotherapeutic patients with hepatocellular carcinoma and its influence on liver function","volume":"21","author":"Zhaohui","year":"2024","journal-title":"Lab Med Clinic"},{"key":"B94","article-title":"The influence of Dc+Cik cell immunotherapy on the effect of postoperative patients with primary liver cancer","volume":"10","author":"Yan","year":"2024","journal-title":"Chin Sci Technol J Database (Abstract Edition) - Med Health"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-6233.2024.10.030","article-title":"Efficacy of toripalimab combined with lenvatinib and Tace in the treatment of advanced hepatocellular carcinoma and its impact on tumor markers and prognosis","volume":"30","author":"Xiaolong","year":"2024","journal-title":"Hebei Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1009-0754.2024.10.012","article-title":"Clinical study on Tace combined with Pd\u20431 inhibitor and Dc\u2043Cik in the treatment of advanced liver cancer","volume":"45","author":"Fan","year":"2024","journal-title":"J Navy Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"104","DOI":"10.15887\/j.cnki.13-1389\/r.2024.21.029","article-title":"The efficacy of camrelizumab combined with lenvatinib mesylate in the treatment of liver cancer and its impact on tumor markers and quality of life","volume":"17","author":"Lifen","year":"2024","journal-title":"Chin J Clin Rational Drug Use"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1008-1704.2024.10.008","article-title":"An evaluation of immune function, clinical efficacy and safety of ramucirumab combined with sorafenib treatment in patients with hepatocellular carcinoma","volume":"29","author":"Xing","year":"2024","journal-title":"Chin Hepatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.19381\/j.issn.1001-7585.2024.23.019","article-title":"The influence of transradial Tace+Haic combined immunotargeted therapy on patients with postoperative liver cancer complicated with portal vein tumor thrombus","volume":"37","author":"Zhong","year":"2024","journal-title":"J Med Theory Pract"},{"key":"B100","article-title":"To explore the clinical effects of apatinib mesylate and sorafenib on patients with advanced liver cancer","volume":"2","author":"Yan","year":"2025","journal-title":"Chin Sci Technol J Database (Abstract Edition) - Med Health"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2095-7629.2025.03.023","article-title":"Analysis of the impact of transarterial chemoembolization combined with targeted therapy on the therapeutic effect of liver cancer patients","volume":"23","author":"Hao","year":"2025","journal-title":"Contemp Med Forum"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-5069.2025.02.026","article-title":"Efficacy and safety of radiofrequency ablation plus atezolizumab in the treatment of patients with unresectable hepatocellular carcinoma","volume":"28","author":"Junyao","year":"2025","journal-title":"J Pract Hepatol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1001-5930.2025.03.037","article-title":"The effect of Pd-1 antibody combined with mfolfox6 hepatic arterial infusion chemotherapy on tumor marker levels and quality of life in patients with advanced primary liver cancer","volume":"40","author":"Dayan","year":"2025","journal-title":"Pract J Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1200\/jco.2013.52.9651","article-title":"Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma","volume":"33","author":"Ren","year":"2015","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-9676.2016.21.028","article-title":"The influence of optimized nursing intervention on anxiety and depression in patients undergoing cell immunotherapy for primary liver cancer","volume":"13","author":"Jie","year":"2016","journal-title":"Nurs Pract Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3969\/j.issn.2095-140X.2016.05.012","article-title":"Effect of cognitive intervention on quality of life, pain degree and clinical efficacy of patients with middle-ad-vanced hepatocellular carcinoma by dc-cik therapy","volume":"28","author":"Hongmei","year":"2016","journal-title":"Med Pharm J Chin People\u2019s Liberation Army"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-3765.2020.04.042","article-title":"The value of early rapid rehabilitation nursing in the treatment of liver cancer patients with surgery combined with sorafenib","volume":"32","author":"Jiao","year":"2020","journal-title":"Strait Pharm J"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2095-7130.2021.03.055","article-title":"Influence of high-quality nursing on quality of life and sleep of patients with primary liver cancer complicated with side effects caused by molecular targeted drugs","volume":"8","author":"Jianzhu","year":"2021","journal-title":"World J Sleep Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-7860.2021.16.030","article-title":"Clinical observation on treating liver cancer by the fuzheng guben method plus targeted therapy","volume":"13","author":"Youjin","year":"2021","journal-title":"Clin J Chin Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1004-4337.2021.01.067","article-title":"Application effect of humanized nursing mode combined with narrative nursing in the treatment of liver cancer with sorafenib and tacrolimus and its influence on subjective well-being and negative emotions","volume":"34","author":"Shuang","year":"2021","journal-title":"J Math Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-0369.2022.01.056","article-title":"Application effects of clinical nursing pathway in patients with primary liver cancer treated by sorafenib","volume":"34","author":"Yali","year":"2022","journal-title":"Med J Chin People\u2019s Health"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2095-7130.2022.05.006","article-title":"To evaluate the effects of tigio combined with sorafenib on adverse mood and sleep quality in patients with primary liver cancer","volume":"9","author":"Yanfang","year":"2022","journal-title":"World Joumnal Sleep Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.19435\/j.1672-1721.2023.15.025","article-title":"Application research of orim self-care model in patients with liver cancer treated with tace combined with sorafenib","volume":"27","author":"Yao","year":"2023","journal-title":"Med Forum"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2095-7130.2023.11.049","article-title":"Analysis of the impact of exercise psychological sleep nursing intervention combined with aromatherapy on targeted immunotherapy combined with sleep disorders in patients with liver cancer","volume":"10","author":"Liuqing","year":"2023","journal-title":"World J Sleep Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.6039\/j.issn.1001-0408.2023.12.15","article-title":"Clinical observation of ruyi jinhuang powder combined with icis in the treatment of advanced liver cancer complicated with dampness and heat syndrome of liver and gallbladder","volume":"34","author":"Dan","year":"2023","journal-title":"China Pharm"},{"key":"B116","article-title":"Observation on the therapeutic effect of qigui zicao oil on capillary hyperplasia after immunotherapy for liver cancer","author":"Yahui","year":"2023"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.19347\/j.cnki.2096-1413.202416034","article-title":"Effects of cloud hospital nursing management model on compliance and adverse reactions of patients with hepatocellular carcinoma treated with targeted drugs","volume":"9","author":"Lijuan","year":"2024","journal-title":"Clin Res Pract"},{"key":"B118","article-title":"The influence of high-quality nursing on the cognition and sleep quality of patients with liver cancer undergoing immunotherapy","volume":"4","author":"Dongyan","year":"2024","journal-title":"Chin Sci Technol J Database: Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.13342\/j.cnki.cjhp.2024.11.015","article-title":"Application of psychological intervention based on dignity therapy in patients receiving targeted therapy for advanced liver cancer","volume":"32","author":"Pei","year":"2024","journal-title":"China J Health Psychol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.20002\/j.issn.1000-7156.2024.02.009","article-title":"Efficacy observation of peiyuan chuzhuo decoction on moderate or advanced liver cancer","volume":"40","author":"Peiying","year":"2024","journal-title":"Shanxi J Traditional Chin Med"},{"key":"B121","article-title":"Clinical study of huqi zhengxiao decoction with lenvatinib in treating 93 patients with stage III hepatitis B related liver cancer","volume":"32","author":"Yang","year":"2024","journal-title":"Chin J Integrated Traditional Chin Western Med Digestion"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1001-1528.2024.12.052","article-title":"The clinical efficacy of shugan jianpi jiedu formula combined with tislelizumab and bevacizumab in patients with advanced liver cancer","volume":"46","author":"Kun","year":"2024","journal-title":"Chin Traditional Patent Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1770579\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:50:12Z","timestamp":1778647812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1770579\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":122,"alternative-id":["10.3389\/fonc.2026.1770579"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1770579","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1770579"}}